Amgen Named Among 15 Best S&P 500 Dividend Stocks for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: Yahoo Finance
- Rating Downgrade: Bernstein downgraded Amgen (AMGN) from Outperform to Market Perform while maintaining a $335 price target, primarily due to the view that 2026 is a 'waiting year' for MariTide, which may dampen investor confidence.
- Potential Risks: Analysts flagged risks including possible impacts on Repatha from Merck's (MRK) pricing of enlicitide, and uncertainty surrounding the significance of Lp(a) outcomes, with clarity expected only after comparisons with Novartis' (NVS) pelicarsen data.
- Acquisition Deal: Amgen announced the acquisition of UK-based Dark Blue Therapeutics for up to $840 million, which will strengthen its oncology pipeline by adding an investigational small molecule targeting acute myeloid leukemia (AML).
- R&D Integration: Amgen plans to integrate Dark Blue into its existing research organization to further support early-stage oncology discovery efforts, demonstrating the company's ongoing commitment to innovative drug development.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 345.87 USD with a low forecast of 272.00 USD and a high forecast of 425.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
11 Buy
7 Hold
1 Sell
Moderate Buy
Current: 349.690
Low
272.00
Averages
345.87
High
425.00
Current: 349.690
Low
272.00
Averages
345.87
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








